

Guest Speaker:

Gui-Qiang Wang, MD



Professor, Chief physician

Chairman, Department of infectious diseases,

Director, Center for liver disease, Peking University first hospital;

President, Society of Infectious Diseases, Chinese Medical Association;

Chairman, Antimicrobial Stewardship Working Committee, Chinese hospital association;

Vice President, Infectious Disease Physicians Branch, Chinese Medical Doctor Association;

Vice President, General Practitioner Education College, Chinese Medical Association;

Member, National Immunization Program Expert Advisory Committee;

Member, National Health Commission Infectious Diseases Standards Committee;

Member, National Health Commission COVID-19 Medical Treatment Expert Group;

Member, National Health Commission COVID-19 Convalescent Plasma Therapy Expert Group;

Member, National Advisory Board of Overseas Anti-epidemic Medical Expert Group;

Member, The State Council Expert Group on Joint prevention and control mechanism of COVID-19;



- Since the outbreak of COVID 19, professor Wang Guiqiang, as a member of the medical treatment expert group of the national health commission, has guided clinical diagnosis and treatment, and participated in the compilation and update of the fifth, sixth and seventh version of the Chinese COVID 19 diagnosis and treatment protocol. Participated in the preparation of the convalescent plasma therapy protocol for COVID-19;
- On behalf of the National Health Commission, he introduced China's diagnosis and treatment protocol to more than 90 countries in the world. On behalf of the National Health Commission, he participated in the press conferences of the state council on joint prevention and control for many times, presented the Protocol, answered questions from the public and the media, and explained COVID-19 prevention and control knowledge to the public.
- Leading the emergency project of the ministry of science and technology "Favipiravir Combined Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study", and leading "The study on the mechanism, outcome and therapeutic intervention of COVID -19 convalescent patients that the nucleic acid reversion".